Anti-podocalyxin antibodies and methods of using the same

Patent metadata

Field	Value
Publication number	US-11090383-B2
Application number	US-201615765233-A
Country	US
Kind code	B2
Filing date	Sep 30, 2016
Priority date	Oct 1, 2015
Publication date	Aug 17, 2021
Grant date	Aug 17, 2021

Abstract

The present invention is directed to anti-podocalyxin antibodies, compositions comprising the same, and methods of using such antibodies and compositions for the prevention, diagnosis and treatment of cancer.

First claim

What is claimed is:

1. An anti-podocalyxin antibody that binds to a podocalyxin tumor epitope, wherein said anti-podocalyxin antibody comprises:
a) a VHCDR1 having an amino acid sequence set forth in SEQ ID NO:33;
a VHCDR2 having an amino acid sequence set forth in SEQ ID NO:36;
a VHCDR3 having an amino acid sequence set forth in SEQ ID NO:39;
a VLCDR1 having an amino acid sequence set forth in SEQ ID NO:42;
a VLCDR2 having an amino acid sequence set forth in SEQ ID NO:45; and
a VLCDR3 having an amino acid sequence set forth in SEQ ID NO:48;

b) a VHCDR1 having an amino acid sequence set forth in SEQ ID NO:34;
a VHCDR2 having an amino acid sequence set forth in SEQ ID NO:37;
a VHCDR3 having an amino acid sequence set forth in SEQ ID NO:40;
a VLCDR1 having an amino acid sequence set forth in SEQ ID NO:43;
a VLCDR2 having an amino acid sequence set forth in SEQ ID NO:46; and
a VLCDR3 having an amino acid sequence set forth in SEQ ID NO:49; or

c) a VHCDR1 having an amino acid sequence set forth in SEQ ID NO:35;
a VHCDR2 having an amino acid sequence set forth in SEQ ID NO:38;
a VHCDR3 having an amino acid sequence set forth in SEQ ID NO:41;
a VLCDR1 having an amino acid sequence set forth in SEQ ID NO:44;
a VLCDR2 having an amino acid sequence set forth in SEQ ID NO:47; and
a VLCDR3 having an amino acid sequence set forth in SEQ ID NO:50.

2. The anti-podocalyxin antibody according to claim 1 , wherein said podocalyxin tumor epitope comprises a post-translational modification of a podocalyxin polypeptide.

3. The anti-podocalyxin antibody according to claim 2 , wherein said post-translational modification of said podocalyxin polypeptide comprises an O-linked glycan moiety that is linked to said podocalyxin polypeptide.

4. The anti-podocalyxin antibody according to claim 2 , wherein said post-translational modification of said podocalyxin polypeptide comprises a glycan moiety that is linked to said podocalyxin polypeptide, wherein said glycan moiety comprises a beta-N-acetyl-galactosamine.

5. The anti-podocalyxin antibody according to claim 4 , wherein said beta-N-acetyl-galactosamine is a terminal beta-N-acetyl-galactosamine.

6. The anti-podocalyxin antibody according to claim 1 , comprising a heavy chain variable region comprising SEQ ID NO: 27.

7. The anti-podocalyxin antibody according to claim 1 , comprising a light chain variable region comprising SEQ ID NO: 29.

8. The anti-podocalyxin antibody according to claim 1 , comprising a heavy chain variable region comprising SEQ ID NO:27 and a light chain variable region comprising SEQ ID NO:29.

9. The anti-podocalyxin antibody according to claim 1 , wherein the anti-podocalyxin antibody is a chimeric, humanized, or human antibody.

10. The anti-podocalyxin antibody according to claim 1 , wherein the anti-podocalyxin antibody is a monoclonal antibody, and/or an antibody fragment.

11. The anti-podocalyxin antibody according to claim 1 , wherein the anti-podocalyxin antibody is an antibody fragment.

12. A modified immune cell, comprising a chimeric antigen receptor (CAR), wherein said CAR comprises the anti-podocalyxin antibody according to claim 11 .

13. The modified immune cell according to claim 12 , wherein said modified immune cell is a modified T cell or a modified NK cell.

14. An antibody-drug conjugate (ADC), comprising the antibody according to claim 1 .

15. A method of inhibiting the growth of a cell that displays a podocalyxin tumor epitope, comprising contacting said cell with the anti-podocalyxin antibody according to claim 1 , the modified immune cell according to claim 12 , or the ADC according to claim 14 .

16. A method of treating a subject having a cancer which expresses a podocalyxin tumor epitope, comprising administering to said subject the anti-podocalyxin antibody according to claim 1 , the modified immune cell according to claim 12 , or the ADC according to claim 14 .

17. A pharmaceutical composition comprising an antibody according to claim 1 , and a pharmaceutically acceptable carrier.

18. A pharmaceutical composition comprising the modified immune cell according to claim 12 , and a pharmaceutically acceptable carrier.

Assignees

• Centre For Drug Res And Development
• Univ British Columbia

Inventors

• Mcnagny Kelly Marshall
• Roskelley Calvin D
• Hughes Michael R
• Canals Hernaez Diana
• Blixt Klas Ola
• Babcook John Stephen
• Bond Christopher John
• Samudio Ismael
• Bergqvist Jan Peter
• Macdonald Katherine Grace
• Von Rossum Anna
• Hedberg Bradley John
• Dean Pamela Megan

Classifications

• A61K40/42

  Cancer antigens · CPC title

• A61K40/31

  Chimeric antigen receptors [CAR] · CPC title

• A61K40/15

  Natural-killer [NK] cells; Natural-killer T [NKT] cells · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title

• A61K47/6803

  Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates · CPC title